Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2022 | Sequencing BCMA-targeted agents in multiple myeloma

Salomon Manier • 27 Aug 2022
IMS 2022
Multiple Myeloma Antibodies Belantamab mafodotin CAR-T Ciltacabtagene autoleucel Elranatamab Idecabtagene vicleucel Teclistamab

Salomon Manier, MD, PhD, Lille University, Lille, France, discusses the feasibility and efficacy of sequencing BCMA-targeted agents in multiple myeloma. Whilst it has been shown that it is possible to sequence BCMA-targeted agents, response rates (RR) are lower when patients that have been exposed to an anti-BCMA agent are treated with a second BCMA-targeted drug. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Salomon Manier

1:54
Ongoing CAR-T trials in earlier lines of therapy in myeloma & strategies to improve efficacy
Salomon Manier • 9 Jun 2023
1:52
Impact of prior BCMA-directed therapy on the efficacy of elranatamab in R/R multiple myeloma
Salomon Manier • 9 Jun 2023
1:55
KarMMa-3 subgroup analysis: ide-cel vs standard regimens in triple-class exposed myeloma
Salomon Manier • 9 Jun 2023
3:33
Determining the optimal sequencing of bispecifics and CAR-T cells in patients with myeloma
Salomon Manier • 13 May 2023

Related Videos

0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
The content of VJHemOnc is intended for healthcare professionals